Comparative Effectiveness of Pharmacogenomics for Treatment of Depression.
J Clin PsychopharmacolAug 10, 2026 (epub)
Andrew A Nierenberg, Masoud Kamali, Dustin J Rabideau et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effectiveness of pharmacogenomics-guided treatment (PGx+GIT) versus guideline-informed treatment (GIT) alone in 201 individuals with major depressive disorder. Over 12 months, both groups showed improvement in well-being, but PGx+GIT did not demonstrate superior outcomes compared to GIT, with a model-based difference in WHO-5 scores of -0.6.
Key findings
- Average well-being improved in both groups over 12 months, with PGx+GIT showing a change of 4.1 and GIT 4.8 in WHO-5 scores.
- PGx+GIT did not result in superior improvement in well-being compared to GIT alone (difference of -0.6).
- The treatment effect was not influenced by depression severity or previous treatment failures.
Why it matters
Understanding the effectiveness of pharmacogenomics in depression treatment is crucial for optimizing patient outcomes. This study suggests that current pharmacogenomic strategies may not provide additional benefits over standard treatment approaches.